Angel Invest Boston

Join Sal's Investment Syndicate: Click Here Unlike software startups that can scale with minimal resources, biotech startups need frequently to rely on collaborations with big strategic players to get to scale. This is an interview with one of the top attorneys in arranging such deals, David Glazer of Morgan Lewis. I learned much from David; I hope you will too. Highlights: Sal Daher Introduces David Glazer of Morgan Lewis, the Biotech Deal Wiz Why Collaborations with Strategic Partners Are So Necessary for Biotech Startups Sal Connected with David by Courtesy of Armon Sharei of SQZ Biotech; David Advised SQZ on the $1.3 Billion Roche Deal Collaborations May Last Ten or Twenty Year; Picking the Right Partner is Crucial A Strategic Partner Can Be Immensely Valuable with Dealing with the Complexities & Cost of Getting a Compound of Technology to Market Strategics Offer Clinical, Regulatory & Commercial Expertise Startups Lack “You got one partner signed up and then the dominoes start to fall, it provid